Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.5% during the second quarter, Holdings Channel.com reports. The firm owned 34,277 shares of the medical instruments supplier’s stock after buying an additional 2,102 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Becton, Dickinson and Company were worth $8,011,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Addenda Capital Inc. grew its holdings in Becton, Dickinson and Company by 17.4% during the second quarter. Addenda Capital Inc. now owns 35,363 shares of the medical instruments supplier’s stock worth $8,265,000 after acquiring an additional 5,240 shares during the period. ORG Partners LLC increased its stake in Becton, Dickinson and Company by 2,250.8% in the 2nd quarter. ORG Partners LLC now owns 1,387 shares of the medical instruments supplier’s stock worth $319,000 after purchasing an additional 1,328 shares in the last quarter. PineStone Asset Management Inc. grew its stake in Becton, Dickinson and Company by 141.6% during the 2nd quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after acquiring an additional 788,735 shares in the last quarter. Riverview Trust Co grew its stake in Becton, Dickinson and Company by 5.9% during the 2nd quarter. Riverview Trust Co now owns 1,257 shares of the medical instruments supplier’s stock valued at $294,000 after acquiring an additional 70 shares in the last quarter. Finally, Bill Few Associates Inc. grew its stake in Becton, Dickinson and Company by 4.0% during the 2nd quarter. Bill Few Associates Inc. now owns 7,389 shares of the medical instruments supplier’s stock valued at $1,727,000 after acquiring an additional 285 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on BDX. Citigroup lowered their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Barclays upped their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. Finally, Evercore ISI cut their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Trading Down 0.9 %

Shares of BDX traded down $2.20 during trading hours on Wednesday, hitting $234.08. 1,075,025 shares of the stock traded hands, compared to its average volume of 1,446,660. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $283.50. The firm has a market capitalization of $67.65 billion, a PE ratio of 51.56, a price-to-earnings-growth ratio of 2.06 and a beta of 0.42. The business has a fifty day moving average of $233.42 and a 200-day moving average of $236.23.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the prior year, the firm posted $2.96 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts expect that Becton, Dickinson and Company will post 13.06 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Insider Transactions at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.31% of the stock is currently owned by insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.